Moderna entities must face infringement suits, UPC rules
UPC rejects jurisdictional challenges from Moderna | Court allows two linked infringement cases over mRNA tech to move forward in The Hague | Ruling finds commercial links between Moderna entities enough to justify its jurisdiction over non-UPC territories.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
24 April 2026 An opinion has put pressure on the CJEU to clarify a long-running grey area that could change the game for how drug makers secure supplementary protection certificates across Europe.